DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge.
about
Smallpox DNA vaccine protects nonhuman primates against lethal monkeypoxUsing the TAP component of the antigen-processing machinery as a molecular adjuvantSide-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primatesStructural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 proteinThe Structure of the Poxvirus A33 Protein Reveals a Dimer of Unique C-Type Lectin-Like DomainsVaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infectionsComplex Minigene Library Vaccination for Discovery of Pre-Erythrocytic Plasmodium T Cell AntigensThe mature virion of ectromelia virus, a pathogenic poxvirus, is capable of intrahepatic spread and can serve as a target for delayed therapy.Prospects for developing an effective particle-mediated DNA vaccine against influenza.A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.Timing of pathogen adaptation to a multicomponent treatment.The larval specific lymphatic filarial ALT-2: induction of protection using protein or DNA vaccination.New classes of orthopoxvirus vaccine candidates by functionally screening a synthetic library for protective antigens.Kinetics and intracellular location of intramolecular disulfide bond formation mediated by the cytoplasmic redox system encoded by vaccinia virus.A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skinProtection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.There is an A33-dependent mechanism for the incorporation of B5-GFP into vaccinia virus extracellular enveloped virions.A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in miceAntibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors.Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 proteinComplete pathway for protein disulfide bond formation encoded by poxvirusesCombinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challengeA protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.The conserved poxvirus L3 virion protein is required for transcription of vaccinia virus early genes.The myristate moiety and amino terminus of vaccinia virus l1 constitute a bipartite functional region needed for entryThe identification of HLA class II-restricted T cell epitopes to vaccinia virus membrane proteins.Evaluating the orthopoxvirus type I interferon-binding molecule as a vaccine target in the vaccinia virus intranasal murine challenge model.The inability of vaccinia virus A33R protein to form intermolecular disulfide-bonded homodimers does not affect the production of infectious extracellular virus.Epitope mapping by random peptide phage display reveals essential residues for vaccinia extracellular enveloped virion spread.DNA vaccines for biodefense.Smallpox vaccines: targets of protective immunity.Mapping and functional analysis of interaction sites within the cytoplasmic domains of the vaccinia virus A33R and A36R envelope proteinsMultivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge.The structure of G4, the poxvirus disulfide oxidoreductase essential for virus maturation and infectivity.Herpes simplex virus 2 (HSV-2) infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine.Human T-cell responses to vaccinia virus envelope proteins.Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organsParainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.
P2860
Q24623839-0398AC9C-369D-4C6D-BED1-153CD8B7D5ABQ25256237-7BAB63F9-A643-42BA-B060-FD3786D4DCD7Q27325586-C96529AF-9C4A-4CEC-AF9D-5D5003A8DB1AQ27647102-F95BD79A-F4B3-4131-BE70-6976D0F6F274Q27658759-4E3F6070-B733-4231-8D3A-1789AC1E6A89Q28362129-717B76CE-CD44-44E0-92B4-4D0DC2DE977EQ28551311-42D4C5AB-DE79-44AA-B44D-9138B4C5F50EQ30223108-B927AB0F-D7C9-4ACE-B24D-5903839E25D0Q30380300-1E0B577F-6553-4130-AFBA-3B44C23EE080Q30445071-817A2A13-1221-457E-A258-DD885D8E51B4Q31131957-795C5986-389B-4FB1-A75A-03F6E4E079DAQ31136230-41EEED45-C868-4633-A692-49A753005BECQ33508318-D5EE8349-E14D-4840-8B99-94D0904B242CQ33664851-E873F1C5-E7C2-45B0-A97F-8A4A72DEF4A9Q33723334-E25CDCB6-FCF0-472A-9064-A85E2EF55333Q33725635-44831232-C280-493C-ADBB-0F526F353C7FQ33857450-17DDFFAC-0A07-4DDB-97D8-8663A80A5203Q33905188-B2FD5CFA-49E8-4711-81FD-9DE329D5063EQ33936717-613381C2-8835-43AE-8793-D8FC51103B2CQ33987410-C12ACD5B-516F-4A5E-86C8-FA5DBD737433Q34039477-D23E4A04-36FF-4B7E-B745-63C8269F1373Q34067229-6FAA71B3-6172-4ADB-871B-A72EA6549825Q34092845-6E798682-8DC8-445C-951C-2F674CB4547CQ34126697-8504D568-FC5D-421B-ADC7-DD005BECCC96Q34142767-D69C925E-B3AF-46FB-B51D-1BC38A790B49Q34259469-E7451D3E-10CD-4693-A45B-F7913E7600B5Q34288498-80BB77E7-ED1D-4A50-BAA8-4F1442A01580Q34289866-4E4E58EE-7D2D-4231-86F4-6FD3E3F95F1EQ34312168-B8390B16-63BD-40E7-94DA-43C3B1A6D684Q34420319-FD69106E-5DE9-4F80-8FEE-470AF620AC9EQ34614260-0CBEBB9F-7ECC-4A19-86C0-338F5F9B032AQ34780607-13C129DE-A934-498E-ABCC-98B04F50C0ABQ34781856-4233F702-3D6A-4809-8AC1-328B46956FA5Q34910424-433A9855-6A9D-4E12-975E-A635B7B4118FQ35023719-D155C6CA-1FF4-4AD9-A60C-5F1CE4636C8FQ35058245-C358CA90-FF79-4270-8A9E-B828E2E9D826Q35101531-D9E27444-D23C-41A5-9EF2-137C3762B9F4Q35192889-7F9C3B7C-7444-44BD-BF1C-2CF97E4D7506Q35226200-86C5A62D-A93A-4784-B6C8-399740184317Q35234767-335C2D66-E322-4513-B913-88E60723C7B3
P2860
DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
DNA vaccination with vaccinia ...... t a lethal poxvirus challenge.
@en
DNA vaccination with vaccinia ...... t a lethal poxvirus challenge.
@nl
type
label
DNA vaccination with vaccinia ...... t a lethal poxvirus challenge.
@en
DNA vaccination with vaccinia ...... t a lethal poxvirus challenge.
@nl
prefLabel
DNA vaccination with vaccinia ...... t a lethal poxvirus challenge.
@en
DNA vaccination with vaccinia ...... t a lethal poxvirus challenge.
@nl
P2093
P356
P1433
P1476
DNA vaccination with vaccinia ...... t a lethal poxvirus challenge.
@en
P2093
Schmaljohn AL
Schmaljohn CS
P304
P356
10.1006/VIRO.1999.0096
P407
P577
2000-01-01T00:00:00Z